Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime
Identifieur interne : 001A11 ( Istex/Corpus ); précédent : 001A10; suivant : 001A12Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime
Auteurs : B. I. Davies ; F. P. V. Maesen ; J. A. Van NoordSource :
- Journal of Antimicrobial Chemotherapy [ 0305-7453 ] ; 1983.
Abstract
Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with Pseudomonas aeruginasa) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses. Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with Ps. aeruginosa or Ps. maltophilia. Some 69% of the 69 Ps. aeruginosa strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 Ps. maltophilia strains were resistant (MICs > 32 mg/l).
Url:
DOI: 10.1093/jac/12.suppl_A.1
Links to Exploration step
ISTEX:5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title><author><name sortKey="Davies, B I" sort="Davies, B I" uniqKey="Davies B" first="B. I." last="Davies">B. I. Davies</name><affiliation><mods:affiliation>De Wever Hospital Heerlen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Maesen, F P V" sort="Maesen, F P V" uniqKey="Maesen F" first="F. P. V." last="Maesen">F. P. V. Maesen</name><affiliation><mods:affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Noord, J A" sort="Van Noord, J A" uniqKey="Van Noord J" first="J. A." last="Van Noord">J. A. Van Noord</name><affiliation><mods:affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A</idno><date when="1983" year="1983">1983</date><idno type="doi">10.1093/jac/12.suppl_A.1</idno><idno type="url">https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title><author><name sortKey="Davies, B I" sort="Davies, B I" uniqKey="Davies B" first="B. I." last="Davies">B. I. Davies</name><affiliation><mods:affiliation>De Wever Hospital Heerlen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Maesen, F P V" sort="Maesen, F P V" uniqKey="Maesen F" first="F. P. V." last="Maesen">F. P. V. Maesen</name><affiliation><mods:affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Van Noord, J A" sort="Van Noord, J A" uniqKey="Van Noord J" first="J. A." last="Van Noord">J. A. Van Noord</name><affiliation><mods:affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Antimicrobial Chemotherapy</title><idno type="ISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1983">1983</date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">suppl_A</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="8">8</biblScope></imprint><idno type="ISSN">0305-7453</idno></series><idno type="istex">5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A</idno><idno type="DOI">10.1093/jac/12.suppl_A.1</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0305-7453</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with Pseudomonas aeruginasa) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses. Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with Ps. aeruginosa or Ps. maltophilia. Some 69% of the 69 Ps. aeruginosa strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 Ps. maltophilia strains were resistant (MICs > 32 mg/l).</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>B. I. Davies</name><affiliations><json:string>De Wever Hospital Heerlen, The Netherlands</json:string></affiliations></json:item><json:item><name>F. P. V. Maesen</name><affiliations><json:string>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</json:string></affiliations></json:item><json:item><name>J. A. van Noord</name><affiliations><json:string>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Articles</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with Pseudomonas aeruginasa) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses. Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with Ps. aeruginosa or Ps. maltophilia. Some 69% of the 69 Ps. aeruginosa strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 Ps. maltophilia strains were resistant (MICs > 32 mg/l).</abstract><qualityIndicators><score>5.195</score><pdfVersion>1.2</pdfVersion><pdfPageSize>620 x 802 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1571</abstractCharCount><pdfWordCount>2195</pdfWordCount><pdfCharCount>13390</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>259</abstractWordCount></qualityIndicators><title>Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title><genre.original><json:string>research-article</json:string></genre.original><genre><json:string>research-article</json:string></genre><host><volume>12</volume><publisherId><json:string>jac</json:string></publisherId><pages><last>8</last><first>1</first></pages><issn><json:string>0305-7453</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2091</json:string></eissn><title>Journal of Antimicrobial Chemotherapy</title></host><categories><wos><json:string>INFECTIOUS DISEASES</json:string><json:string>PHARMACOLOGY & PHARMACY</json:string><json:string>MICROBIOLOGY</json:string></wos></categories><publicationDate>1983</publicationDate><copyrightDate>1983</copyrightDate><doi><json:string>10.1093/jac/12.suppl_A.1</json:string></doi><id>5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>OUP</p></availability><date>1983</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title><author><persName><forename type="first">B. I.</forename><surname>Davies</surname></persName><affiliation>De Wever Hospital Heerlen, The Netherlands</affiliation></author><author><persName><forename type="first">F. P. V.</forename><surname>Maesen</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">J. A.</forename><surname>van Noord</surname></persName><affiliation></affiliation></author></analytic><monogr><title level="j">Journal of Antimicrobial Chemotherapy</title><idno type="pISSN">0305-7453</idno><idno type="eISSN">1460-2091</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1983"></date><biblScope unit="volume">12</biblScope><biblScope unit="supplement">suppl_A</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="8">8</biblScope></imprint></monogr><idno type="istex">5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A</idno><idno type="DOI">10.1093/jac/12.suppl_A.1</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1983</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with Pseudomonas aeruginasa) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses. Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with Ps. aeruginosa or Ps. maltophilia. Some 69% of the 69 Ps. aeruginosa strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 Ps. maltophilia strains were resistant (MICs > 32 mg/l).</p></abstract><textClass><keywords scheme="keyword"><list><item><term>Articles</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1983">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-15">References added</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-22">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">jac</journal-id><journal-id journal-id-type="archive">jac</journal-id><journal-id journal-id-type="publisher-id">jac</journal-id><journal-title>Journal of Antimicrobial Chemotherapy</journal-title><issn pub-type="ppub">0305-7453</issn><issn pub-type="epub">1460-2091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/jac/12.suppl_A.1</article-id><article-categories><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Davies</surname><given-names>B. I.</given-names></name><xref ref-type="aff" rid="au1"></xref></contrib><contrib contrib-type="author"><name><surname>Maesen</surname><given-names>F. P. V.</given-names></name><xref ref-type="aff" rid="au2"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Noord</surname><given-names>J. A.</given-names></name><xref ref-type="aff" rid="au2"><sup>*</sup></xref></contrib><aff id="au1"><institution>De Wever Hospital</institution> <addr-line>Heerlen, The Netherlands</addr-line></aff><aff id="au2"><label>*</label><institution>Departments of Medical Microbiology and Respiratory Diseases</institution> <addr-line>Heerlen, The Netherlands</addr-line></aff></contrib-group><pub-date pub-type="ppub"><year>1983</year></pub-date><volume>12</volume><issue>suppl_A</issue><fpage>1</fpage><lpage>8</lpage><copyright-statement>© 1983 The British Society for Antimicrobial Chemotherapy</copyright-statement><copyright-year>1983</copyright-year><abstract><p>Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with <italic>Pseudomonas aeruginasa</italic>) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses.</p><p>Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with <italic>Ps. aeruginosa</italic> or <italic>Ps. maltophilia</italic>.</p><p>Some 69% of the 69 <italic>Ps. aeruginosa</italic> strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 <italic>Ps. maltophilia</italic> strains were resistant (MICs > 32 mg/l).</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime</title></titleInfo><name type="personal"><namePart type="given">B. I.</namePart><namePart type="family">Davies</namePart><affiliation>De Wever Hospital Heerlen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F. P. V.</namePart><namePart type="family">Maesen</namePart><affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. A.</namePart><namePart type="family">van Noord</namePart><affiliation>Departments of Medical Microbiology and Respiratory Diseases Heerlen, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>Articles</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">1983</dateIssued><copyrightDate encoding="w3cdtf">1983</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Two groups of patients were treated with ceftazidime intramuscularly for 10 days. There were 34 patients with acute purulent exacerbations of chronic bronchitis of whom 20 received 1-g and the other 14 2-g injections. A further 38 patients with chronic recurrent respiratory infections (mostly severe bronchiectasis associated with Pseudomonas aeruginasa) were treated with 2-g injections twice or thrice daily. Blood and sputum concentrations of ceftazidime were measured microbiologically on the first day of treatment. The peak serum concentrations (34.4 and 37.8 mg/l after the 2 different doses) were reached between ½ and 1 h after the injections and the mean areas under the concentration-time curves were 131 mg/l. h and 149 mg/l. h, respectively. The sputum concentrations after the 2 doses reached 3.0 mg/l after 1 g, and 3.5 mg/l after the 2 g doses. Sputum cultures before and after treatment showed that 32 of the 34 patients with chronic bronchitis had negative cultures at the end of the treatment although 6 had further infections by the 17th study day. Among the 38 patients with relapsing infections with Gram-negative organisms, one died early in the treatment course and one later on, but 28 of the 37 patients had negative sputum cultures on day 11 and 17 of the 36 remaining were clear of infection on day 17. The recurrences were all associated with Ps. aeruginosa or Ps. maltophilia. Some 69% of the 69 Ps. aeruginosa strains were inhibited by 2 mg/l of ceftadizime and 91% by 4 mg/l. All 3 Ps. maltophilia strains were resistant (MICs > 32 mg/l).</abstract><relatedItem type="host"><titleInfo><title>Journal of Antimicrobial Chemotherapy</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0305-7453</identifier><identifier type="eISSN">1460-2091</identifier><identifier type="PublisherID">jac</identifier><identifier type="PublisherID-hwp">jac</identifier><part><date>1983</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="supplement"><number>suppl_A</number></detail><extent unit="pages"><start>1</start><end>8</end></extent></part></relatedItem><identifier type="istex">5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A</identifier><identifier type="DOI">10.1093/jac/12.suppl_A.1</identifier><accessCondition type="use and reproduction" contentType="copyright">© 1983 The British Society for Antimicrobial Chemotherapy</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/annexes/pdf</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">INFECTIOUS DISEASES</classCode><classCode scheme="WOS">PHARMACOLOGY & PHARMACY</classCode><classCode scheme="WOS">MICROBIOLOGY</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Informatique/explor/ScrumV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001A11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Informatique
|area= ScrumV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:5D9EFE5705973BCEAD1DEBE466BC5F30CD4D2F6A
|texte= Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime
}}
| This area was generated with Dilib version V0.6.39. |  |